SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-18-127599
Filing Date
2018-04-24
Accepted
2018-04-24 06:18:35
Documents
8
Period of Report
2018-06-11
Effectiveness Date
2018-04-24

Document Format Files

Seq Description Document Type Size
1 DEF 14A d573774ddef14a.htm DEF 14A 985129
2 GRAPHIC g573774g06d72.jpg GRAPHIC 104189
3 GRAPHIC g573774g06r49.jpg GRAPHIC 114854
4 GRAPHIC g573774g23x22.jpg GRAPHIC 144132
5 GRAPHIC g573774g82k09.jpg GRAPHIC 28546
6 GRAPHIC g573774g91g84.jpg GRAPHIC 57344
7 GRAPHIC g573774new01.jpg GRAPHIC 382681
8 GRAPHIC g573774new02.jpg GRAPHIC 184982
  Complete submission text file 0001193125-18-127599.txt   2376545
Mailing Address 501 CANAL BLVD POINT RICHMOND TECH CNTR. RICHMOND CA 94804
Business Address 501 CANAL BLVD POINT RICHMOND TECH CNTR. RICHMOND CA 94804 5109706000
SANGAMO THERAPEUTICS, INC (Filer) CIK: 0001001233 (see all company filings)

IRS No.: 680359556 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-30171 | Film No.: 18770021
SIC: 2836 Biological Products, (No Diagnostic Substances)